WHO rolls out important guidelines on GLP-1 weight-loss treatments

The World Health Organization has released its first-ever guidelines for the safe and effective use of GLP-1 medications for weight loss. Learn what the new recommendations mean.

The World Health Organization has officially released global guidance for the use of GLP-1 classes of drugs to treat obesity, a landmark step in how the world approaches weight-related illness. These therapies, including medicines like semaglutide (known as Wegovy/Ozempic), liraglutide (Saxenda) and tirzepatide (Zepbound/Mounjaro), are now recommended, under certain conditions, as part of long-term care for adults living with obesity.

The new guidelines of WHO

In its new guidance, WHO emphasizes that obesity should no longer be seen simply as a matter of lifestyle or willpower. Instead, it is recognized as a chronic, relapsing disease that requires long-term, comprehensive care. The recommendations from WHO offer a conditional endorsement for long-term GLP-1 therapy in adults with obesity (excluding pregnant women). This means that in clinical settings, these medicines can be prescribed, but only when combined with other obesity-management measures like healthy diet, regular physical activity, and behavioral support.

How can GLP-1 drugs benefit?

The decision reflects growing evidence that GLP-1 drugs can help significantly reduce weight and improve metabolic health. However, WHO also stresses that medication alone won’t solve the obesity crisis. Long-term care, lifestyle changes, and systemic public health measures remain essential.

Part of the guideline’s emphasis is on fairness and accessibility. WHO warns that if these treatments are not made affordable and widely available, they could worsen global health inequalities. Many countries currently face supply constraints, high costs, and infrastructure challenges, which could prevent large-scale use of GLP-1 therapies.

Recognizing obesity as a chronic disease is a major shift. It acknowledges that for many, obesity is not a simple outcome of lifestyle choices, but often involves complex factors like genetics, environment, biology, and social conditions.

The challenges related to the medications

Despite the positive move, there are real obstacles. WHO notes that even with increased production, GLP-1 therapies may only reach fewer than 10% of all eligible people by 2030. This limited reach is due to high costs, supply-chain constraints, and uneven health-system readiness across countries.

Another concern is long-term safety and sustainability of such treatments. Since GLP-1 drugs are relatively new for weight-loss use, there are still unknowns about their long-term effects, what happens if a patient stops treatment, and whether health systems globally can support ongoing prescriptions.